Výsledky vyhledávání - "Dacarbazine/therapeutic use"

Autor: Hottinger, A.F., Hegi, M.E., Baumert, B.G.

Publikováno v: Current opinion in neurology, vol. 29, no. 6, pp. 782-788

The management of patients suffering from low-grade gliomas (LGGs) remains a challenge in absence of a definite curative therapy. The median survival is highly variable, from 2 years (high-risk disease) to over 15 years (low risk). The aim of this re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::c4d6693861352d9fcee4ba1c71401230
https://serval.unil.ch/resource/serval:BIB_AA45A63A4CB1.P001/REF.pdf

Zobrazit plný text záznamu

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

Autor: Mathilde C.M. Kouwenhoven, Karima Mokhtari, René-Olivier Mirimanoff, Marie-France Hamou, Christian Hartmann, Danielle Martinet, Pieter Wesseling, Roger Stupp, A. von Deimling, M. J. van den Bent, Michael Weller, N Besuchet Schmutz, Wanyu L. Lambiv, Robert-Charles Janzer, Thierry Gorlia, Annie-Claire Diserens, Monika E. Hegi, Pierre Bady, Warren P. Mason

Publikováno v: Acta Neuropathologica, 123(6), 841-852. Springer Verlag
Acta Neuropathologica, 123, 841-52
Acta Neuropathologica, 123(6), 841-852. Springer-Verlag
Hegi, M E, Janzer, R C, Lambiv, W L, Gorlia, T, Kouwenhoven, M C, Hartmann, C, von Deimling, A, Martinet, D, Besuchet Schmutz, N, Diserens, A C, Hamou, M F, Bady, P, Weller, M, van den Bent, M J, Mason, W P, Mirimanoff, R O, Stupp, R, Mokhtari, K & Wesseling, P 2012, ' Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial ', Acta Neuropathologica, vol. 123, no. 6, pp. 841-852 . https://doi.org/10.1007/s00401-011-0938-4
Acta Neuropathologica, 123, 6, pp. 841-52
Acta neuropathologica
Acta Neuropathologica, vol. 123, no. 6, pp. 841-852

Item does not contain fulltext Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1a5a1d3c56b8ef520162e875697e9dd
https://hdl.handle.net/2066/109138

Zobrazit plný text záznamu

Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter—still a dilemma?

Autor: Hegi, M.E., Stupp, R.

Publikováno v: Neuro-oncology, vol. 17, no. 11, pp. 1425-1427

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b2f5b33f538725853901c05af2d50363
https://europepmc.org/articles/PMC4648310/

Zobrazit plný text záznamu

MGMT gene silencing and benefit from temozolomide in glioblastoma

Autor: Peter Hau, Thierry Gorlia, Monika E. Hegi, Roger Stupp, René O. Mirimanoff, Johan M. Kros, Johannes A. Hainfellner, Marie-France Hamou, Warren P. Mason, Annie-Claire Diserens, Robert C. Janzer, Nicolas de Tribolet, J. Gregory Cairncross, Jacoline E C Bromberg, Luigi Mariani, Michael Weller

Publikováno v: New England Journal of Medicine, vol. 352, no. 10, pp. 997-1003
New England Journal of Medicine, 352(10), 997-1003. Massachussetts Medical Society

BACKGROUND: Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating age

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a592cf5c8deeeb0769ad0cf23f99cede
https://hdl.handle.net/1765/54130

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání